EA200701740A1 - Кристаллическое основание транс-1-((1r,3s)-3-фенил-6-хлороиндан-1-ил)-3,3-диметилпиперазина - Google Patents

Кристаллическое основание транс-1-((1r,3s)-3-фенил-6-хлороиндан-1-ил)-3,3-диметилпиперазина

Info

Publication number
EA200701740A1
EA200701740A1 EA200701740A EA200701740A EA200701740A1 EA 200701740 A1 EA200701740 A1 EA 200701740A1 EA 200701740 A EA200701740 A EA 200701740A EA 200701740 A EA200701740 A EA 200701740A EA 200701740 A1 EA200701740 A1 EA 200701740A1
Authority
EA
Eurasian Patent Office
Prior art keywords
chloroindan
phenyl
trans
dimethylpiperazzine
crystallic
Prior art date
Application number
EA200701740A
Other languages
English (en)
Other versions
EA017631B1 (ru
Inventor
Бенни Банг-Андерсен
Хейди Лопес Де Диего
Original Assignee
Х. Лундбекк А/С
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=37908539&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=EA200701740(A1) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by Х. Лундбекк А/С filed Critical Х. Лундбекк А/С
Publication of EA200701740A1 publication Critical patent/EA200701740A1/ru
Publication of EA017631B1 publication Critical patent/EA017631B1/ru

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D295/00—Heterocyclic compounds containing polymethylene-imine rings with at least five ring members, 3-azabicyclo [3.2.2] nonane, piperazine, morpholine or thiomorpholine rings, having only hydrogen atoms directly attached to the ring carbon atoms
    • C07D295/04—Heterocyclic compounds containing polymethylene-imine rings with at least five ring members, 3-azabicyclo [3.2.2] nonane, piperazine, morpholine or thiomorpholine rings, having only hydrogen atoms directly attached to the ring carbon atoms with substituted hydrocarbon radicals attached to ring nitrogen atoms
    • C07D295/06—Heterocyclic compounds containing polymethylene-imine rings with at least five ring members, 3-azabicyclo [3.2.2] nonane, piperazine, morpholine or thiomorpholine rings, having only hydrogen atoms directly attached to the ring carbon atoms with substituted hydrocarbon radicals attached to ring nitrogen atoms substituted by halogen atoms or nitro radicals
    • C07D295/073—Heterocyclic compounds containing polymethylene-imine rings with at least five ring members, 3-azabicyclo [3.2.2] nonane, piperazine, morpholine or thiomorpholine rings, having only hydrogen atoms directly attached to the ring carbon atoms with substituted hydrocarbon radicals attached to ring nitrogen atoms substituted by halogen atoms or nitro radicals with the ring nitrogen atoms and the substituents separated by carbocyclic rings or by carbon chains interrupted by carbocyclic rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/06—Antimigraine agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/18—Antipsychotics, i.e. neuroleptics; Drugs for mania or schizophrenia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/20—Hypnotics; Sedatives
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/22—Anxiolytics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/24—Antidepressants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/30—Drugs for disorders of the nervous system for treating abuse or dependence
    • A61P25/32—Alcohol-abuse
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/30—Drugs for disorders of the nervous system for treating abuse or dependence
    • A61P25/34—Tobacco-abuse
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/30—Drugs for disorders of the nervous system for treating abuse or dependence
    • A61P25/36—Opioid-abuse

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • General Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Medicinal Chemistry (AREA)
  • Neurology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Neurosurgery (AREA)
  • Biomedical Technology (AREA)
  • Addiction (AREA)
  • Psychiatry (AREA)
  • Pain & Pain Management (AREA)
  • Anesthesiology (AREA)
  • Epidemiology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)

Abstract

Кристаллическое основание соединения транс-1-((1R,3S)-3-фенил-6-хлороиндан-1-ил)-3,3-диметилпиперазина, процесс получения очищенного свободного основания или солей данного соединения, фармацевтические композиции, содержащие основание и их медицинское применение, включая лечение шизофрении и других психотических расстройств.
EA200701740A 2005-02-16 2006-02-14 Кристаллическое основание транс-1-((1r,3s)-3-фенил-6-хлороиндан-1-ил)-3,3-диметилпиперазина EA017631B1 (ru)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
DKPA200500239 2005-02-16
PCT/DK2006/000088 WO2006086986A1 (en) 2005-02-16 2006-02-14 Crystalline base of trans-1-((1r,3s)-6-chloro-3-phenylindan-1-yl)-3,3-dimethylpiperazine

Publications (2)

Publication Number Publication Date
EA200701740A1 true EA200701740A1 (ru) 2007-12-28
EA017631B1 EA017631B1 (ru) 2013-02-28

Family

ID=37908539

Family Applications (1)

Application Number Title Priority Date Filing Date
EA200701740A EA017631B1 (ru) 2005-02-16 2006-02-14 Кристаллическое основание транс-1-((1r,3s)-3-фенил-6-хлороиндан-1-ил)-3,3-диметилпиперазина

Country Status (29)

Country Link
US (2) US7648991B2 (ru)
EP (1) EP1853576B1 (ru)
JP (1) JP5055135B2 (ru)
KR (1) KR101386387B1 (ru)
CN (1) CN101119983B (ru)
AR (1) AR052909A1 (ru)
AT (1) ATE515501T1 (ru)
AU (1) AU2006215957B9 (ru)
BR (1) BRPI0607436B8 (ru)
CA (1) CA2597622C (ru)
CY (1) CY1111857T1 (ru)
DK (1) DK1853576T3 (ru)
EA (1) EA017631B1 (ru)
ES (1) ES2368786T3 (ru)
HK (1) HK1117525A1 (ru)
HR (1) HRP20110645T1 (ru)
IL (1) IL184551A (ru)
MX (1) MX2007009980A (ru)
MY (1) MY148683A (ru)
NO (1) NO339863B1 (ru)
NZ (1) NZ556397A (ru)
PL (1) PL1853576T3 (ru)
PT (1) PT1853576E (ru)
RS (1) RS51944B (ru)
SI (1) SI1853576T1 (ru)
TW (1) TWI376373B (ru)
UA (1) UA95901C2 (ru)
WO (1) WO2006086986A1 (ru)
ZA (1) ZA200705982B (ru)

Families Citing this family (8)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
AU2004265021B2 (en) * 2003-08-18 2010-05-27 H. Lundbeck A/S Succinate and malonate salt of trans-4-(IR,3S)-6-chloro-3-phenylindan-1-yl)-1,2,2-trimethylpiperazine and the use as a medicament
TWI453198B (zh) * 2005-02-16 2014-09-21 Lundbeck & Co As H 製造反式-1-((1r,3s)-6-氯基-3-苯基茚滿-1-基) -3 , 3 -二甲基六氫吡與其鹽類之方法及製造4-((1r , 3s）-6 -氯基-3-苯基茚滿-1-基 )-1,2,2-三甲基六氫吡與其鹽類之方法
TWI376373B (en) * 2005-02-16 2012-11-11 Lundbeck & Co As H Crystalline base of a pharmaceutical compound
WO2009135495A1 (en) * 2008-05-07 2009-11-12 H. Lundbeck A/S Method for treating cognitive deficits
EP2344163A1 (en) * 2008-10-03 2011-07-20 H. Lundbeck A/S Oral formulation
LT2720989T (lt) * 2011-06-20 2016-11-25 H. Lundbeck A/S Deuterinti 1-piperazin-3-fenilindanai, skirti šizofrenijos gydymui
US20210395208A1 (en) 2018-10-29 2021-12-23 H. Lundeck A/S Amorphous compounds of formula (i) and amorphous compounds of formula (i) salts
WO2020114853A1 (en) 2018-12-03 2020-06-11 H. Lundbeck A/S Prodrugs of 4-((1r,3s)-6-chloro-3-phenyl-2,3-dihydro-1h-inden-1-yl)-1,2,2-trimethylpiperazine and 4-((1/r,3s)-6-chloro-3-(phenyl-d5)-2,3-dihydro-1h-inden-1-yl)-2,2-dimethy-1-(methyl-d3)piperazine

Family Cites Families (29)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4031216A (en) 1974-08-12 1977-06-21 Knoll A.G. Chemische Fabriken 3-(3,4-Dialkoxy-benzyl)-3-methyl-piperazines
IE50867B1 (en) 1980-02-29 1986-08-06 Kefalas As Indane derivatives
DE3139970A1 (de) 1981-10-08 1983-04-28 Boehringer Mannheim Gmbh, 6800 Mannheim Neue carbonsaeurederivate, verfahren zu ihrer herstellung sowie diese verbindungen enthaltende arzneimittel
US5026853A (en) 1987-04-01 1991-06-25 Janssen Pharmaceutica N.V. 4-substituted-2(or 3)aminocarbonyl-1-piperazineacetamide
US5466806A (en) 1989-02-08 1995-11-14 Biochem Pharma Inc. Processes for preparing substituted 1,3-oxathiolanes with antiviral properties
CZ287406B6 (cs) 1991-11-05 2000-11-15 Smithkline Beecham Corporation Indanové a indenové deriváty, způsob jejich výroby a farmaceutické prostředky s jejich obsahem
CA2091204C (en) 1992-03-11 1997-04-08 Ronald J. Mattson Antiischemic-piperazinyl and piperidinyl-cyclohexanes
DK55192D0 (da) 1992-04-28 1992-04-28 Lundbeck & Co As H 1-piperazino-1,2-dihydroindenderivater
JPH06184132A (ja) 1992-12-22 1994-07-05 Kotobuki Seiyaku Kk ベンゾフラン誘導体及びその製造方法並びに尿酸排泄剤
CA2176500C (en) 1993-11-30 1999-09-28 George J. Quallich Process for preparing a chiral tetralone
CA2132411A1 (en) 1994-09-19 1996-03-20 Michael Trani Enzymatic esterification of long-chain racemic acids and alcohols
US6455736B1 (en) 1994-12-16 2002-09-24 Uop Llc Process for preparation of pharmaceutically desired sertraline and sertraline analogs
US6410794B1 (en) 1994-12-16 2002-06-25 Uop Llc Process for preparation of pharmaceutically desired chiral tetralone from tetralones
US5807897A (en) 1996-03-01 1998-09-15 Zeneca Limited Aminotetralin derivative and compositions and method of use thereof
US6268367B1 (en) 1998-02-23 2001-07-31 Zymogenetics, Inc. Piperazine derivatives for treating bone deficit conditions
ES2211080T3 (es) 1998-05-01 2004-07-01 Pfizer Products Inc. Procedimiento para la produccion de sertralina tetralona enantiomericamente pura u opticamente enriquecida usando cromatografia continua.
CN1229351C (zh) 1998-05-22 2005-11-30 西奥斯股份有限公司 杂环化合物和治疗心力衰竭及其它疾病的方法
DE19824470A1 (de) 1998-05-30 1999-12-02 Boehringer Ingelheim Pharma Neue Neurokininantagonisten, Verfahren zu ihrer Herstellung und diese Verbindungen enthaltende pharmazeutische Zusammensetzungen
GB9818916D0 (en) 1998-08-28 1998-10-21 Smithkline Beecham Plc Use
FR2786769B1 (fr) 1998-12-04 2002-10-25 Synthelabo Derives de 2,5-diazabicyclo[2.2.1]heptane, leur preparation et leur application en therapeutique
JP2000351773A (ja) 1999-06-08 2000-12-19 Yamanouchi Pharmaceut Co Ltd フラン誘導体からなる医薬
EP1059302A1 (en) 1999-06-08 2000-12-13 Aventis Pharma Deutschland GmbH Factor VIIa inhibitors
AR031520A1 (es) 1999-06-11 2003-09-24 Vertex Pharma Un compuesto inhibidor de aspartilo proteasa, una composicion que lo comprende y un metodo para tratar un paciente con dicha composicion
US6369226B1 (en) 1999-06-21 2002-04-09 Agouron Pharmaceuticals, Inc. Substituted benzamide inhibitors of rhinovirus 3C protease
IN187170B (ru) 2000-01-04 2002-02-23 Sun Pharmaceutical Ind Ltd
AU2004265021B2 (en) 2003-08-18 2010-05-27 H. Lundbeck A/S Succinate and malonate salt of trans-4-(IR,3S)-6-chloro-3-phenylindan-1-yl)-1,2,2-trimethylpiperazine and the use as a medicament
TWI453198B (zh) 2005-02-16 2014-09-21 Lundbeck & Co As H 製造反式-1-((1r,3s)-6-氯基-3-苯基茚滿-1-基) -3 , 3 -二甲基六氫吡與其鹽類之方法及製造4-((1r , 3s）-6 -氯基-3-苯基茚滿-1-基 )-1,2,2-三甲基六氫吡與其鹽類之方法
MX2007009816A (es) 2005-02-16 2007-09-07 Lundbeck & Co As H Sales de tartrato y de malato de trans-1-((1r,3s)-6-cloro-3- fenilindan-1-i1)-3,3-dimetilpiperazina.
TWI376373B (en) 2005-02-16 2012-11-11 Lundbeck & Co As H Crystalline base of a pharmaceutical compound

Also Published As

Publication number Publication date
IL184551A0 (en) 2007-10-31
MX2007009980A (es) 2007-09-26
US20100105699A1 (en) 2010-04-29
BRPI0607436B8 (pt) 2021-05-25
PL1853576T3 (pl) 2011-12-30
US7648991B2 (en) 2010-01-19
BRPI0607436A2 (pt) 2010-04-06
JP5055135B2 (ja) 2012-10-24
TWI376373B (en) 2012-11-11
AU2006215957A1 (en) 2006-08-24
IL184551A (en) 2014-05-28
SI1853576T1 (sl) 2011-11-30
NO339863B1 (no) 2017-02-13
EP1853576A1 (en) 2007-11-14
AU2006215957B2 (en) 2011-09-29
NO20074639L (no) 2007-09-12
NZ556397A (en) 2010-06-25
EP1853576B1 (en) 2011-07-06
US20080153848A1 (en) 2008-06-26
CA2597622A1 (en) 2006-08-24
CA2597622C (en) 2013-11-12
KR101386387B1 (ko) 2014-04-25
HRP20110645T1 (hr) 2011-10-31
CN101119983A (zh) 2008-02-06
EA017631B1 (ru) 2013-02-28
ZA200705982B (en) 2009-06-24
AU2006215957B9 (en) 2012-02-16
KR20070103414A (ko) 2007-10-23
UA95901C2 (en) 2011-09-26
MY148683A (en) 2013-05-31
RS51944B (en) 2012-02-29
CN101119983B (zh) 2014-11-12
US8450324B2 (en) 2013-05-28
JP2008530040A (ja) 2008-08-07
HK1117525A1 (en) 2009-01-16
BRPI0607436B1 (pt) 2020-10-06
TW200640890A (en) 2006-12-01
PT1853576E (pt) 2011-09-28
DK1853576T3 (da) 2011-09-26
ATE515501T1 (de) 2011-07-15
CY1111857T1 (el) 2015-11-04
WO2006086986A1 (en) 2006-08-24
ES2368786T3 (es) 2011-11-22
AR052909A1 (es) 2007-04-11

Similar Documents

Publication Publication Date Title
NO20061153L (no) Trans-1-(6-klor-3-fenylindan-1-yl)-3,3-dimetylpiperazin
EA200701740A1 (ru) Кристаллическое основание транс-1-((1r,3s)-3-фенил-6-хлороиндан-1-ил)-3,3-диметилпиперазина
NO20056130L (no) Nye substituerte 3-svovelindoler
EA200601798A1 (ru) Замещенные соединения морфолина для лечения расстройств центральной нервной системы
EA200901373A1 (ru) Аминогетероциклические соединения
NO20045589L (no) Nye forbindelser
EA200500203A1 (ru) Новый способ синтеза и новая кристаллическая форма агомелатина и фармацевтические композиции, которые её содержат
NO20082266L (no) Nye 1-azabicykloalkylderivater for behandling av psykotiske og neurodegenerative forstyrrelser
IS2533B (is) (S)-2-N-própýlamínó-5-hýdroxýetralín sem D3-gerandefni
MX2007003108A (es) Compuestos imidazo-3-il-amina sustituidos y biciclicos.
CR9223A (es) 18-metil-19-nor-17-pregn-4-en-21, 17-carbolactonas,asi como preparaciones farmaceuticas que las contienen
NO20074593L (no) Tartrat- og malatsalter av trans-1-(6-klor-3-fenylindan-1-yl)-3,3-dimetylpiperazin
TW200716582A (en) Process for making a pharmaceutical compound
DK1853232T3 (da) Stabil krystallin form af bifeprunox mesylat, doseringsformer deraf og fremgangsmåder for deres anvendelse
ES2186550B2 (es) Nuevos derivados de oxazolidinonas como antibacterianos.
EA200701856A1 (ru) Тетрагидропиридоазепин-8-оны и родственные соединения для лечения шизофрении
DE602004007672D1 (de) Zur behandlung von zns-erkrankungen geeignete piperazinylchinolinderivate
DK1670903T3 (da) Behandling af neurodegenerative sygdomme
EA200701737A1 (ru) Тартраты и малаты транс-1-((1r,3s)-6-хлор-3-фенилиндан-1-ил)-3,3-диметилпиперазина
ATE518853T1 (de) Verbindungen zur behandlung entzündlicher erkrankungen
EA200600443A1 (ru) Транс-1-(6-хлор-3-фенилиндан-1-ил)-3,3-диметилпиперазин
UA108342C2 (uk) Спосіб одержання 4-((1r,3s)-6-хлор-3-феніліндан-1-іл)-1,2,2-триметилпіперазину або його солі (варіанти), цис-(1s,3s)-6-хлор-3-феніліндан-1-ол, цис-(1s,3s)-3-заміщений-5-хлор-1-феніліндан та транс-1-((1r,3s)-6-хлор-3-феніліндан-1-іл)-3,3-диметилпіперазин
DE602005017663D1 (de) Tetralin- und indanderivate und anwendungen davon
DK1755583T3 (da) Anvendelse af neboglamin til behandling af skizofreni
UA88930C2 (en) Amide derivatives